Please login to the form below

Not currently logged in
Email:
Password:

sickle cell disease

This page shows the latest sickle cell disease news and features for those working in and with pharma, biotech and healthcare.

Daily brief: Global Blood confident of sickle cell success, Breathalyser wins engineering award, Swiss biotech raises funds

Daily brief: Global Blood confident of sickle cell success, Breathalyser wins engineering award, Swiss biotech raises funds

The latest from pharma, biotech and healthcare. Global Blood Therapeutics stops enrolment in sickle cell disease. ... Global Blood Therapeutics (GBT) has stopped enrolment in trials for its sickle cell disease (SCD) therapy voxelotor due to initial,

Latest news

More from news
Approximately 5 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Gevokizumab plus IP for use of IL-1 beta targeting antibodies for cardiovascular disease. ... 425 (upfront 80). Calimmune (US). CSL (AU). Company acquisition. Preclinical haematopoietic stem cell therapy for sickle cell disease.

  • Deal Watch November 2016 Deal Watch November 2016

    antibody, SelG1, after the completion of a phase II study in patients with sickle cell disease (SCD). ... lead product - SelG1, anti-P-selection mAb for reduction of vaso-occlusive pain crises in patients with sickle cell.

  • Deal Watch October 2015 Deal Watch October 2015

    The collaboration between CRISPR Therapeutics and Vertex will evaluate the use of CRISPR/Cas9 in a number of diseases with defined genetic targets, including cystic fibrosis and sickle cell disease. ... 17, 200. CRISPR Therapeutics/ Vertex Pharmaceuticals

  • Pharma deals during August 2014 Pharma deals during August 2014

    It also has potential utility in treating systemic sclerosis-related Interstitial Lung Disease. ... It is currently being investigated as the sole stem cell source in a phase I/II study to treat haematological malignancies such as leukaemia and lymphoma

  • Pharma deals during July 2014 Pharma deals during July 2014

    Cosmo Technologies is an Irish-domiciled subsidiary of Italian-based Cosmo Pharmaceuticals, which has a focus in gastrointestinal disease and dermatology. ... for sickle cell disease (SCD), called Aes-103.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Cellerant appoints William Reed as VP clinical development Cellerant appoints William Reed as VP clinical development

    He has previous experience in treatments for blood conditions, spending time as director, clinical research and medical affairs at Cerus, where he worked on a programme for sickle cell disease. ... transplantation, leukaemia and acute radiation syndrome

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics